Skip to main content

Table 2 Association between VEGF genotypes and overall survival

From: Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy

Genotypes Case No. Deaths No. (%)* MST (95% CI, month) Crude HR (95% CI) P Adjusted HR (95% CI) P
VEGF-460T > C (rs833061)      
   TT 33 28 (84.9) 16.0 (11.0-25.0) 1.00   1.00  
   CT 67 47 (70.2) 21.0 (17.0-32.0) 0.60 (0.37-0.95) 0.031 0.56 (0.34-0.90) 0.018
   CC 24 17 (70.8) 27.0 (10.0-36.0) 0.75 (0.41-1.37) 0.347 0.67 (0.36-1.26) 0.212
   CT+CC 91 64 (70.3) 21.0 (17.0-31.0) 0.63 (0.40-0.99) 0.043 0.58 (0.37-0.92) 0.022
VEGF -634G > C (rs2010963)      
   GG 57 40 (70.2) 23.0 (16.0-36.0) 1.00   1.00  
   CG 41 34 (82.9) 17.0 (13.0-25.0) 1.20 (0.76-1.90) 0.440 1.17 (0.74-1.88) 0.502
   CC 26 18 (69.2) 12.0 (9.0-29.0) 1.25 (0.71-2.18) 0.436 1.28 (0.72-2.28) 0.399
   CG+CC 67 52 (76.1) 17.0 (12.0-24.0) 1.22 (0.80-1.84) 0.356 1.21 (0.79-1.84) 0.379
VEGF +936C > T (rs3025039)      
   CC 92 68 (73.9) 21.0 (16.0-29.0) 1.00   1.00  
   CT 30 22 (73.3) 17.0 (11.0-29.0) 1.08 (0.67-1.75) 0.742 1.00 (0.60-1.66) 0.992
   TT 2 2 (100) 14.5 (9.0-20.0) 2.14 (0.52-8.80) 0.291 1.95 (0.46-8.29) 0.367
   CT+TT 32 24 (75.0) 17.0 (11.0-28.0) 1.13 (0.71-1.80) 0.606 1.05 (0.65-1.71) 0.839
  1. Abbreviation: MST, median survival time.
  2. * Percentage of deaths in each stratum
  3. † P values were calculated using the log-rank test in the univariate analysis.
  4. ‡ P values were obtained from the Cox hazards model with adjustment for age, sex, smoking status, tumor histology, KPS score, tumor stage, application of chemotherapy and radiotherapy dose.
\